Abstract
The authors present a case of a 45- year- old female patient, who has been previously treated for psoriasis with guselkumab. In 2021 after COVID vaccination seropapules on erythematous background and annular blisters developed. Early clinical presentation indicated Sweet syndrome or IgA-mediated autoimmune bullous diseases, however histological examination showed intraepidermal eosinophilic spongiosis with IgG and C3 deposits along the basal membrane – concluding the diagnosis of bullous pemphigoid. ELISA test revealed both anti-BP180 and anti-type VII collagen antibody positivity, the latter being atypical in bullous pemphigoid. Despite the usual immunosuppressant therapy – corticosteroid and later azathioprine – the clinical symptoms showed progression. Due to the therapy resistance, rituximab was administered, which resulted in complete regression of skin sypmtoms. During regular follow-up stable remission has been achieved. As described in the published medical case reports of atypical bullous pemphigoid, we suspect that the main pathogenetic factor could be epitope spreading caused by the 10-year history of psoriasis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
